Pipeline zoals vastgelegd in de Atlas op Aug 25, 2026. Bedrijven passen hun pipelines regelmatig aan — controleer altijd de eigen materialen en regelgevingsdossiers van het bedrijf.
In één alinea
Vertex is a large, profitable biotechnology company best known for transforming cystic fibrosis treatment. It partnered with CRISPR Therapeutics on Casgevy and leads its commercialisation — the part of bringing a gene-editing medicine to patients that requires global regulatory, manufacturing and reimbursement capability rather than laboratory science.
Vertex Pharmaceuticals, founded in 1989, is a commercial-stage biotechnology company with a franchise in cystic fibrosis modulators. It collaborated with CRISPR Therapeutics on exagamglogene autotemcel and leads its development and commercialisation. Its presence in the field illustrates a structural point: the scientific origin of an editing medicine and the organisation capable of delivering it globally are frequently not the same company.
Geen beleggingsadvies
Dit profiel is educatieve informatie samengesteld uit openbare bekendmakingen. Het is geen aanbeveling om een effect te kopen, verkopen of aan te houden, en het is geen mening over de vooruitzichten van het bedrijf. Biotechnologie is sterk speculatief en de meeste klinische programma's mislukken.
Volledige disclaimers →
Written by The CRISPR Atlas editorial teamLast updated Aug 25, 2026
Connected in the Atlas
Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.
